Trevi Therapeutics Phase IIb update a major de-risking event, says B. Riley

Trevi Therapeutics (TRVI) on Thursday reported confirmation of the clearing sample size re-estimation for the Phase IIb CORAL trial in idiopathic pulmonary fibrosis patients with chronic cough, requiring no increase in sample size and keeping the trial on track for readout in the first half of 2025, B. Riley tells investors in a research note. The firm believes the update, which noted that the trial has reached 75% of target enrollment, is a major de-risking event to Phase IIb CORAL readout, particularly given the relatively small 20-patient sample size on top dose cohort that points to Trevi being on track for likely replicating the best-in-indication Phase IIa CANAL trial efficacy findings. B. Riley also sees a positive read-through to the anticipated Phase IIa RIVER trial readout in the first quarter of 2025 Haduvio in refractory chronic cough.